Abstract
Type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) are both facets of the metabolic syndrome, associated with obesity and insulin resistance. MASLD, a term that replaces non-alcoholic fatty liver disease (NAFLD), occurs in up to 70% of people with T2D. Not only do T2D and MASLD commonly co-occur, but there is a synergistic, bidirectional relationship between these conditions, meaning that each affects the natural disease course of the other. As such, it is important for those caring for people with T2D to recognize the importance of this co-diagnosis. In this summary, we detail the synergistic relationship between T2D and MASLD, explain the current challenges in recognizing this common co-diagnosis and suggest practical approaches for those caring for people with T2D to improve the diagnosis and treatment of MASLD.
| Original language | English |
|---|---|
| Pages (from-to) | 1-5 |
| Number of pages | 5 |
| Journal | touchREVIEWS in Endocrinology |
| Volume | 20 |
| Issue number | 2 |
| Early online date | 23 Apr 2024 |
| DOIs | |
| Publication status | Published - Oct 2024 |
Keywords
- Alcohol-related liver disease
- cardiometabolic risk factors
- liver cirrhosis
- metabolic and alcoholic-related steatotic liver disease
- metabolic dysfunction-associated steatohepatitis
- metabolic dysfunction-associated steatotic liver disease
- non-alcoholic fatty liver disease
- non-alcoholic steatohepatitis
- steatotic liver disease
- type 2 diabetes
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
